Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

​​​​​Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more

PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more

Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more

Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more

PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more

Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place,... read more

PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more